ESR1 and breast cancer: Hormone therapy is the first-line option for all patients with ER-expressing breast cancer, where tamoxifen (Nolvadex, AstraZeneca Pharmaceutics, Cambridge, UK), which is a selective receptor estrogen modulator, is the drug commonly used because of its ability to reduce disease recurrence by half [42].